PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10629357-11	2000	At the end of treatment, the intent to-treat analysis on 342 patients showed a statistically significant effect of eptastigmine compared to placebo on both ADAS-Cog (p = 0.047) and CDR-SB (p = 0.010).	physostigmine heptyl	115-127	alkylglycerone phosphate synthase	Homo sapiens	156-160
10987987-1	2000	Eptastigmine, a potent and long-lasting cholinesterase inhibitor on age-related memory deficits, was studied.	physostigmine heptyl	0-12	butyrylcholinesterase	Rattus norvegicus	40-54
10884065-5	2000	20 min earlier, significantly reduced the memory deficit Pretreatment with eptastigmine, a second generation cholinesterase inhibitor, given orally 100 min before the cannabinoid agonist, relieved the memory impairment without affecting CP 55,940-induced behavioural alterations such as reduced spontaneous motor activity, analgesia and hind limb splaying.	physostigmine heptyl	75-87	butyrylcholinesterase	Rattus norvegicus	109-123
10840182-1	2000	The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning.	physostigmine heptyl	83-102	acetylcholinesterase	Rattus norvegicus	4-24
10840182-1	2000	The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning.	physostigmine heptyl	83-102	acetylcholinesterase	Rattus norvegicus	26-30
10840182-1	2000	The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning.	physostigmine heptyl	104-107	acetylcholinesterase	Rattus norvegicus	4-24
10372951-1	1999	Two patients meeting the criteria for probable Alzheimer disease (AD) who were participating in a phase 3 clinical program with eptastigmine, a cholinesterase inhibitor, committed suicide.	physostigmine heptyl	128-140	butyrylcholinesterase	Homo sapiens	144-158
10026388-11	1999	Thus patients treated with eptastigmine for 2 years had a benefit of 8.5 points on ADAS-Cog and 3.8 points on IADL.	physostigmine heptyl	27-39	alkylglycerone phosphate synthase	Homo sapiens	83-87
9702845-1	1998	Eptastigmine is a new acetylcholinesterase (AChE) inhibitor currently under development for the symptomatic treatment of Alzheimer disease.	physostigmine heptyl	0-12	acetylcholinesterase (Cartwright blood group)	Homo sapiens	22-42
10078713-2	1999	BACKGROUND: Eptastigmine is a centrally acting cholinesterase inhibitor.	physostigmine heptyl	12-24	butyrylcholinesterase	Homo sapiens	47-61
10078713-8	1999	At the end of treatment, the intent-to-treat analysis on 463 patients showed a dose-dependent effect of eptastigmine on all efficacy variables, with a statistically significant effect of the 20 mg three times daily dose compared with placebo on the ADAS-Cog, CIBIC-Plus, and IADL.	physostigmine heptyl	104-116	alkylglycerone phosphate synthase	Homo sapiens	249-253
10078713-9	1999	Patients on eptastigmine 15 mg three times daily performed significantly better than placebo-treated patients only on the ADAS-Cog.	physostigmine heptyl	12-24	alkylglycerone phosphate synthase	Homo sapiens	122-126
9876959-15	1998	In a post hoc subgroup analysis by staging, the effect size of eptastigmine was found to be greater in the most severely impaired patients (Global Deterioration Scale rating of 4 and 5 at screening) reaching statistical significance in both ADAS-Cog (p=0.007) and CIBIC-Plus (p=0.038).	physostigmine heptyl	63-75	alkylglycerone phosphate synthase	Homo sapiens	241-245
9876965-5	1998	All patients received oral eptastigmine, a new cholinesterase inhibitor, for 1 month.	physostigmine heptyl	27-39	butyrylcholinesterase	Homo sapiens	47-61
9923589-0	1998	Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment.	physostigmine heptyl	83-95	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
9702845-1	1998	Eptastigmine is a new acetylcholinesterase (AChE) inhibitor currently under development for the symptomatic treatment of Alzheimer disease.	physostigmine heptyl	0-12	acetylcholinesterase (Cartwright blood group)	Homo sapiens	44-48
9702845-5	1998	Pharmacodynamic activity of eptastigmine was evaluated with an assay of AChE activity in red blood cells.	physostigmine heptyl	28-40	acetylcholinesterase (Cartwright blood group)	Homo sapiens	72-76
9702845-11	1998	The mean (+/- SEM) maximum inhibition of AChE activity (Imax) was 14.5+/-3.3%, 20.4+/-2.3%, 28.7+/-2.9%, 45.2+/-1.3% and 53.6+/-2.9% after placebo, 8 mg, 20 mg, 32 mg, and 40 mg of eptastigmine, respectively.	physostigmine heptyl	181-193	acetylcholinesterase (Cartwright blood group)	Homo sapiens	41-45
9702845-14	1998	Single oral doses of eptastigmine produce sustained, dose-related inhibition of AChE activity.	physostigmine heptyl	21-33	acetylcholinesterase (Cartwright blood group)	Homo sapiens	80-84
9681667-4	1998	Acetylcholinesterase activity in red blood cells was assayed 24 h after drug administration as a biological marker of eptastigmine plasma concentrations.	physostigmine heptyl	118-130	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
9681667-5	1998	RESULTS: Mean maximum acetylcholinesterase inhibition (Imax) was 39.9% after eptastigmine without food and 33.1% after eptastigmine with food.	physostigmine heptyl	77-89	acetylcholinesterase (Cartwright blood group)	Homo sapiens	22-42
9681667-5	1998	RESULTS: Mean maximum acetylcholinesterase inhibition (Imax) was 39.9% after eptastigmine without food and 33.1% after eptastigmine with food.	physostigmine heptyl	119-131	acetylcholinesterase (Cartwright blood group)	Homo sapiens	22-42
9681667-7	1998	Areas under the curve of acetylcholinesterase per cent inhibition from 0 to 8 h after drug administration (AUC0-8) were 198% h after eptastigmine without food and 124% h after eptastigmine with food.	physostigmine heptyl	133-145	acetylcholinesterase (Cartwright blood group)	Homo sapiens	25-45
9681667-7	1998	Areas under the curve of acetylcholinesterase per cent inhibition from 0 to 8 h after drug administration (AUC0-8) were 198% h after eptastigmine without food and 124% h after eptastigmine with food.	physostigmine heptyl	176-188	acetylcholinesterase (Cartwright blood group)	Homo sapiens	25-45
9681667-10	1998	CONCLUSIONS: The ingestion of food significantly reduces the bioavailability of eptastigmine estimated by the assay of red blood cell acetylcholinesterase activity.	physostigmine heptyl	80-92	acetylcholinesterase (Cartwright blood group)	Homo sapiens	134-154
8978935-5	1997	Heptyl-physostigmine (eptastigmine), a carbamate cholinesterase inhibitor with prolonged time of action improved cerebral blood flow in most regions, with the exception of the ischemic core.	physostigmine heptyl	0-20	butyrylcholinesterase	Rattus norvegicus	49-63
9596354-0	1998	Effect of the subchronic treatment with the acetylcholinesterase inhibitor heptastigmine on central cholinergic transmission and memory impairment in aged rats.	physostigmine heptyl	75-88	acetylcholinesterase	Rattus norvegicus	44-64
9596354-1	1998	The effect of subchronic administration of the acetylcholinesterase (AChE) inhibitor heptastigmine (HEP 0.6 mg/kg s.c. daily for 15 days) was investigated on cortical extracellular acetylcholine (ACh) levels and on memory function in aged male rats (26 months old at the beginning of the experiments) using microdialysis and behavioural techniques.	physostigmine heptyl	85-98	acetylcholinesterase	Rattus norvegicus	47-67
9596354-1	1998	The effect of subchronic administration of the acetylcholinesterase (AChE) inhibitor heptastigmine (HEP 0.6 mg/kg s.c. daily for 15 days) was investigated on cortical extracellular acetylcholine (ACh) levels and on memory function in aged male rats (26 months old at the beginning of the experiments) using microdialysis and behavioural techniques.	physostigmine heptyl	85-98	acetylcholinesterase	Rattus norvegicus	69-73
8978935-5	1997	Heptyl-physostigmine (eptastigmine), a carbamate cholinesterase inhibitor with prolonged time of action improved cerebral blood flow in most regions, with the exception of the ischemic core.	physostigmine heptyl	22-34	butyrylcholinesterase	Rattus norvegicus	49-63
8975781-11	1996	Eptastigmine alone assisted the recovery of the brain ChE activities.	physostigmine heptyl	0-12	butyrylcholinesterase	Mus musculus	54-57
8823240-14	1996	In the eptastigmine group, performances on all tests and scales improved with an inverted U-shaped relation to average daily acetylcholinesterase inhibition.	physostigmine heptyl	7-19	acetylcholinesterase (Cartwright blood group)	Homo sapiens	125-145
8823240-15	1996	CONCLUSIONS: This study shows that doses of 40 to 60 mg per day of eptastigmine are relatively safe and well tolerated and that moderate acetylcholinesterase inhibition is associated with maximal cognitive efficacy.	physostigmine heptyl	67-79	acetylcholinesterase (Cartwright blood group)	Homo sapiens	137-157
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	physostigmine heptyl	112-131	butyrylcholinesterase	Rattus norvegicus	54-68
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	physostigmine heptyl	133-136	butyrylcholinesterase	Rattus norvegicus	54-68
8545521-11	1995	Acetylcholinesterase inhibitors heptylphysostigmine, galanthamine (0.63-2.5 mg/kg, IP) and tacrine (0.63-10.0 mg/kg, IP) all enhanced the rate of decrement of olfactory investigation when administered alone, but had differential effects on aggression.	physostigmine heptyl	32-51	acetylcholinesterase	Mus musculus	0-20
7624918-0	1995	A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.	physostigmine heptyl	105-117	acetylcholinesterase (Cartwright blood group)	Homo sapiens	54-74
7586900-8	1995	Pharmacokinetic data pertaining to eptastigmine, a third cholinesterase inhibitor, is more limited.	physostigmine heptyl	35-47	butyrylcholinesterase	Homo sapiens	57-71
8474626-3	1993	However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit.	physostigmine heptyl	93-113	butyrylcholinesterase	Rattus norvegicus	37-51
7608318-1	1995	Eptastigmine is a long-lasting acetyl-cholinesterase inhibitor, currently being developed for the symptomatic treatment of Alzheimer"s disease.	physostigmine heptyl	0-12	butyrylcholinesterase	Homo sapiens	38-52
7832976-2	1994	The compound is structurally related to the cholinesterase inhibitor heptylphysostigmine (MF 201) because the angular methyl group of the esoroline nucleus has been changed into a bridging carbon and the anilinic nitrogen has been replaced by a methylene group.	physostigmine heptyl	69-88	butyrylcholinesterase	Homo sapiens	44-58
7934317-1	1994	Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy).	physostigmine heptyl	0-19	butyrylcholinesterase	Homo sapiens	41-55
7934317-1	1994	Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy).	physostigmine heptyl	0-19	butyrylcholinesterase	Homo sapiens	57-60
7934317-1	1994	Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy).	physostigmine heptyl	21-23	butyrylcholinesterase	Homo sapiens	41-55
7934317-1	1994	Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy).	physostigmine heptyl	21-23	butyrylcholinesterase	Homo sapiens	57-60
7934317-4	1994	In one subject given 0.6 mg/kg of HP, concentration in plasma was 0.68 ng/ml at 2 h and gradually declined to below the detection limit by 4 h. Peak plasma and RBC ChE inhibitions of 31.2% and 55.8% were achieved at 2 h for both with a 0.6 mg/kg dose.	physostigmine heptyl	34-36	butyrylcholinesterase	Homo sapiens	164-167
7934317-7	1994	Higher levels of ChE inhibition can be achieved with HP than with its parent compound, Phy.	physostigmine heptyl	53-55	butyrylcholinesterase	Homo sapiens	17-20
7913496-1	1994	A microdialysis technique was used to investigate the effect of physostigmine (PHY) and heptylphysostigmine (HEP), administered systemically or locally, on the extracellular levels of acetyl-choline (ACh), norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat.	physostigmine heptyl	88-107	acyl-CoA thioesterase 12	Rattus norvegicus	200-203
7913496-5	1994	Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels.	physostigmine heptyl	101-104	butyrylcholinesterase	Rattus norvegicus	40-54
7913496-5	1994	Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels.	physostigmine heptyl	101-104	acyl-CoA thioesterase 12	Rattus norvegicus	160-163
7913496-7	1994	HEP produced a longer lasting inhibition of cholinesterase and a more prolonged elevation of ACh in cerebral cortex than PHY.	physostigmine heptyl	0-3	butyrylcholinesterase	Rattus norvegicus	44-58
7913496-7	1994	HEP produced a longer lasting inhibition of cholinesterase and a more prolonged elevation of ACh in cerebral cortex than PHY.	physostigmine heptyl	0-3	acyl-CoA thioesterase 12	Rattus norvegicus	93-96
8243558-5	1993	Similar results were obtained after administration of the reversible inhibitor of cholinesterase, eptastigmine.	physostigmine heptyl	98-110	butyrylcholinesterase	Rattus norvegicus	82-96
8233096-3	1993	However, it did potentiate the elevation of extracellular acetylcholine levels produced by a dose of systemic heptylphysostigmine which inhibited 25% of cortical and 40% of plasma cholinesterase activity.	physostigmine heptyl	110-129	butyrylcholinesterase	Rattus norvegicus	180-194
8314923-0	1993	Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats.	physostigmine heptyl	52-64	butyrylcholinesterase	Rattus norvegicus	21-35
8314923-1	1993	The cerebrovascular and metabolic effects of the novel cholinesterase inhibitor eptastigmine were tested in conscious rats.	physostigmine heptyl	80-92	butyrylcholinesterase	Rattus norvegicus	55-69
8314923-7	1993	A linear correlation between rCBF and rCGU was observed both in saline (r = 0.871) and eptastigmine (r = 0.873)-injected animals but the slope of the regression line of rCBF on rCGU was significantly higher (p < 0.01) in the eptastigmine group (2.863 +/- 0.266) than in the controls that received saline (1.00 +/- 0.094).	physostigmine heptyl	87-99	CCAAT/enhancer binding protein zeta	Rattus norvegicus	29-33
8314923-7	1993	A linear correlation between rCBF and rCGU was observed both in saline (r = 0.871) and eptastigmine (r = 0.873)-injected animals but the slope of the regression line of rCBF on rCGU was significantly higher (p < 0.01) in the eptastigmine group (2.863 +/- 0.266) than in the controls that received saline (1.00 +/- 0.094).	physostigmine heptyl	87-99	CCAAT/enhancer binding protein zeta	Rattus norvegicus	169-173
8314923-7	1993	A linear correlation between rCBF and rCGU was observed both in saline (r = 0.871) and eptastigmine (r = 0.873)-injected animals but the slope of the regression line of rCBF on rCGU was significantly higher (p < 0.01) in the eptastigmine group (2.863 +/- 0.266) than in the controls that received saline (1.00 +/- 0.094).	physostigmine heptyl	228-240	CCAAT/enhancer binding protein zeta	Rattus norvegicus	29-33
8314923-11	1993	It is concluded that eptastigmine induces a long-lasting increase in rCBF and a significant enhancement of the rCBF:rCGU ratio in most regions.	physostigmine heptyl	21-33	CCAAT/enhancer binding protein zeta	Rattus norvegicus	69-73
8314923-11	1993	It is concluded that eptastigmine induces a long-lasting increase in rCBF and a significant enhancement of the rCBF:rCGU ratio in most regions.	physostigmine heptyl	21-33	CCAAT/enhancer binding protein zeta	Rattus norvegicus	111-115
8343985-4	1993	The assay has been applied to the determination of plasma and red cell cholinesterase activity in volunteers over 60 years of age treated with a single oral dose of 30 mg eptastigmine.	physostigmine heptyl	171-183	butyrylcholinesterase	Homo sapiens	71-85
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	physostigmine heptyl	45-64	butyrylcholinesterase	Rattus norvegicus	87-101
1494302-0	1992	Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL).	physostigmine heptyl	65-84	acetylcholinesterase (Cartwright blood group)	Homo sapiens	56-60
1494302-0	1992	Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL).	physostigmine heptyl	86-90	acetylcholinesterase (Cartwright blood group)	Homo sapiens	56-60
1494302-1	1992	Heptylphysostigmine (HPTL), a derivative of the AChE inhibitor physostigmine (PHY), is under investigation as a therapeutic agent in Alzheimer"s disease.	physostigmine heptyl	0-19	acetylcholinesterase (Cartwright blood group)	Homo sapiens	48-52
1494302-1	1992	Heptylphysostigmine (HPTL), a derivative of the AChE inhibitor physostigmine (PHY), is under investigation as a therapeutic agent in Alzheimer"s disease.	physostigmine heptyl	21-25	acetylcholinesterase (Cartwright blood group)	Homo sapiens	48-52
8299673-1	1993	Eptastigmine is a new cholinesterase inhibitor, which may be potentially useful for the symptomatic treatment of Alzheimer"s disease.	physostigmine heptyl	0-12	butyrylcholinesterase	Homo sapiens	22-36
8299673-7	1993	The results indicate that oral administration of eptastigmine to elderly subjects produces long lasting inhibition of cholinesterase activity in plasma and in red blood cells.	physostigmine heptyl	49-61	butyrylcholinesterase	Homo sapiens	118-132
8336517-0	1993	Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs.	physostigmine heptyl	0-12	growth hormone releasing hormone	Canis lupus familiaris	32-36
8336517-0	1993	Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs.	physostigmine heptyl	0-12	somatotropin	Canis lupus familiaris	48-62
8336517-1	1993	The aim of the present work was to evaluate the effect on the growth hormone (GH) secretion of eptastigmine, a new long-acting cholinesterase inhibitor, in unanesthetized beagle dogs.	physostigmine heptyl	95-107	somatotropin	Canis lupus familiaris	62-76
8336517-1	1993	The aim of the present work was to evaluate the effect on the growth hormone (GH) secretion of eptastigmine, a new long-acting cholinesterase inhibitor, in unanesthetized beagle dogs.	physostigmine heptyl	95-107	somatotropin	Canis lupus familiaris	78-80
8336517-1	1993	The aim of the present work was to evaluate the effect on the growth hormone (GH) secretion of eptastigmine, a new long-acting cholinesterase inhibitor, in unanesthetized beagle dogs.	physostigmine heptyl	95-107	butyrylcholinesterase	Canis lupus familiaris	127-141
8336517-7	1993	There was a significant logistic relationship (r = 0.601, P < 0.01) between the administered dose of eptastigmine and the log-transformed areas under the GH plasma concentration-time curve (AUC) with a calculated ED50 for eptastigmine of 0.63 +/- 0.36 mg/kg.	physostigmine heptyl	104-116	somatotropin	Canis lupus familiaris	157-159
8336517-7	1993	There was a significant logistic relationship (r = 0.601, P < 0.01) between the administered dose of eptastigmine and the log-transformed areas under the GH plasma concentration-time curve (AUC) with a calculated ED50 for eptastigmine of 0.63 +/- 0.36 mg/kg.	physostigmine heptyl	225-237	somatotropin	Canis lupus familiaris	157-159
8336517-15	1993	These data indicate that eptastigmine is very effective in augmenting basal and stimulated GH secretion in old dog.	physostigmine heptyl	25-37	somatotropin	Canis lupus familiaris	91-93
1393597-4	1992	The effect of three clinically significant acetylcholinesterase inhibitors, heptyl-physostigmine, physostigmine and edrophonium, on aqueous-soluble acetylcholinesterase molecular forms of the caudate-putamen was investigated.	physostigmine heptyl	76-96	acetylcholinesterase (Cartwright blood group)	Homo sapiens	148-168
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	physostigmine heptyl	45-64	butyrylcholinesterase	Rattus norvegicus	103-106
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	physostigmine heptyl	66-71	butyrylcholinesterase	Rattus norvegicus	103-106
1564524-0	1992	Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.	physostigmine heptyl	36-56	butyrylcholinesterase	Homo sapiens	73-87
1601960-1	1992	An analytical method was developed with sensitivity to detect clinically significant concentrations of heptylphysostigmine (HP), a new physostigmine derivative with potent and long-lasting inhibitory activity on cholinesterase.	physostigmine heptyl	103-122	butyrylcholinesterase	Homo sapiens	212-226
1635892-1	1992	Heptastigmine is a new long acting cholinesterase inhibitor that affects behaviour in a number of cognitive tests in animals.	physostigmine heptyl	0-13	butyrylcholinesterase	Rattus norvegicus	35-49
1601960-1	1992	An analytical method was developed with sensitivity to detect clinically significant concentrations of heptylphysostigmine (HP), a new physostigmine derivative with potent and long-lasting inhibitory activity on cholinesterase.	physostigmine heptyl	124-126	butyrylcholinesterase	Homo sapiens	212-226
1763105-0	1991	The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.	physostigmine heptyl	26-46	butyrylcholinesterase	Rattus norvegicus	54-68
1782985-0	1991	Kinetics of cholinesterase inhibition by eptastigmine in man.	physostigmine heptyl	41-53	butyrylcholinesterase	Homo sapiens	12-26
2608162-0	1989	The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.	physostigmine heptyl	14-34	butyrylcholinesterase	Rattus norvegicus	42-56
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	0-20	butyrylcholinesterase	Rattus norvegicus	154-168
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	0-20	butyrylcholinesterase	Rattus norvegicus	170-173
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	22-32	butyrylcholinesterase	Rattus norvegicus	154-168
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	22-32	butyrylcholinesterase	Rattus norvegicus	170-173